Back to top
more

Kodiak Sciences (KOD)

(Delayed Data from NSDQ)

$7.31 USD

7.31
301,046

+0.66 (9.92%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $7.33 +0.02 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.

Zacks Equity Research

Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?

by Zacks Equity Research

Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.

Zacks Equity Research

What's in Store for Select Medical (SEM) Earnings in Q1?

by Zacks Equity Research

Select Medical (SEM) Q1 results are likely to reflect improvement in patient volumes.

Zacks Equity Research

Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View

by Zacks Equity Research

Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.

Zacks Equity Research

What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

Zacks Equity Research

Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study

by Zacks Equity Research

Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.

Zacks Equity Research

Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

Zacks Equity Research

Why Kodiak Sciences (KOD) Stock Might be a Great Pick

by Zacks Equity Research

Kodiak Sciences (KOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Kodiak Sciences' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kodiak Sciences

Sanghamitra Saha headshot

Biotech Rally Sends Nasdaq to 9000: ETFs in Focus

by Sanghamitra Saha

Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.

Zacks Equity Research

Is Kodiak Sciences (KOD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (KOD) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Kodiak Sciences Inc. (KOD) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Kodiak Sciences Inc. (KOD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Will Kodiak Sciences Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kodiak Sciences.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Kodiak Sciences Inc. (KOD) Stock

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Sweta Killa headshot

5 Stocks That Pushed Russell 2000 ETF Higher

by Sweta Killa

Inside the best performing stocks of the Russell 2000 ETF.

Zacks Equity Research

Kodiak Sciences' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kodiak Sciences.

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kodiak Sciences Inc. (KOD).

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kodiak Sciences Inc. (KOD).

Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble

Tirthankar Chakraborty headshot

Wall Street Takes Notice of These 4 Stocks - Should You?

by Tirthankar Chakraborty

With the market in a volatile state, Wall Street's top investors are sorting the most valuable stocks - should you follow?